2025-523052-32-00CompletedPhase 1
A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Oct 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 1 Aug 2025
- Start date
- 17 Oct 2025
- Lead sponsor
- Gan & Lee Pharmaceuticals USA Corp.
- Diseases
- Type 1 diabetes
- EU CT number
- 2025-523052-32-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 14
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.